Potential For New Glaucoma Therapies

In this interview from Glaucoma 360, Gary Novack discusses two new therapies that may soon be available to treat glaucoma. One is a new class of drugs called Rho kinase inhibitors that lower IOP by simultaneously inhibiting Rho kinase to increase fluid outflow through the trabecular meshwork and inhibiting the norepinephrine transporter to reduce fluid production. Bausch & Lomb is close to launching a new class of an existing drug, latanoprostene bunod (Vesneo), a novel nitric oxide-donating prostaglandin F2-alpha analog for reducing IOP in patients with glaucoma and ocular hypertension. Even though the pipeline isn’t flooded with new drugs, Novack says the good news is businesses believe glaucoma treatment remains a good investment.